Italian national HTA Programme approved at the State-Regions Assembly

09

Oct 2017

Agreement on the national HTA programme for medical devices has been reached between the central and regional authorities during the last Assembly. The main player in this context will be the Cabina di Regia per l’HTA, a national steering committee for HTA created in 2015-2016 by the Ministry of Health including representatives of the Ministry of Health, four Regions, The national agency for regional healthcare (AGENAS), and the Italian medicine agency (AIFA).

The steering committee will coordinate activities aimed at the production of the following deliverables:

  • List of technologies notified for evaluation;
  • List of technologies prioritized for assessment;
  • HTA reports for prioritized technologies;
  • Recommendations for appropriate use within the healthcare system (appraisal reports);
  • Working plan for the coordination of the activities related to the national HTA programme.

The deliverables will be disseminated among all the decisional levels of the national healthcare system, from the national commission for the essential level of care (Commissione Nazionale LEA) to the regional directorates that will circulate them across hospitals and regional procurement units.

The main elements of the programme are here described:

Notification of technologies and prioritization of assessments

An online notification form will manage notifications. Any stakeholder, including manufacturers and patients or citizens, will have the chance to submit a technology for assessment. The steering committee will be responsible for the prioritization of assessments and, to assure transparency, independence, and equity, seven prioritization criteria have been defined.

HTA reports production

The national agency for regional healthcare (AGENAS) will coordinate assessment activities performed by public and private collaborative centers disseminated across the country. The expertise of collaborative centers will be assessed according to a set of criteria defined by AGENAS together with the national institute of health (ISS). Draft HTA reports will be externally peer-reviewed and open to public consultation for 30 days. Final versions will be released to the public after approval from the steering committee.

Definition of recommendations for appropriate use

The steering committee will be responsible for the production of recommendations based on the judgment provided by a national appraisal network within 60 days from the production of the HTA report. Four kinds of recommendation will be possible

  • The technology does not have (yet) prerequisites for widespread use;
  • The introduction of the technology will lead to benefits;
  • The technology is recommended for use only within research framework aimed to generate scientific evidence;
  • The technology can be used only after data on real effectiveness and costs have been collected.

Stakeholders affected by the recommendations can contest the decision and claim for re-definition of recommendations within 30 days.    

Links with procurement

HTA reports will be disseminated among regional procurement units and will have an actual role in final decisions about procurement. Procurements units will have to report periodically to the steering committee about the use of the HTA documents within the decisional process.  

Working groups

Three working groups will assist the steering committee in the different tasks:

  • National appraisal network working group
  • Methods, training, and communication working group
  • Programme monitoring working group

Please, find a link to the full-text of the National HTA Programme (in Italian) here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more